Last updated: 3 July 2024 at 8:09pm EST

Dr. Edward M. Kaye Net Worth




The estimated Net Worth of Edward M. Md Kaye is at least $6.64 Milhão dollars as of 20 May 2024. Dr Kaye owns over 42,350 units of Stoke Therapeutics stock worth over $397,980 and over the last 12 years he sold STOK stock worth over $5,286,881. In addition, he makes $958,046 as CEO & Director at Stoke Therapeutics.

Dr Kaye STOK stock SEC Form 4 insiders trading

Dr has made over 19 trades of the Stoke Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 42,350 units of STOK stock worth $653,461 on 20 May 2024.

The largest trade he's ever made was exercising 50,000 units of Stoke Therapeutics stock on 16 December 2019 worth over $30,000. On average, Dr trades about 4,898 units every 42 days since 2012. As of 20 May 2024 he still owns at least 27,000 units of Stoke Therapeutics stock.

You can see the complete history of Dr Kaye stock trades at the bottom of the page.





Dr. Edward M. Kaye biography

Dr. Edward M. Kaye is the CEO & Director at Stoke Therapeutics.

What is the salary of Dr Kaye?

As the CEO & Director of Stoke Therapeutics, the total compensation of Dr Kaye at Stoke Therapeutics is $958,046. There are 1 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.



How old is Dr Kaye?

Dr Kaye is 72, he's been the CEO & Director of Stoke Therapeutics since . There are no older and 20 younger executives at Stoke Therapeutics.

What's Dr Kaye's mailing address?

Edward's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.

Insiders trading at Stoke Therapeutics

Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., eTrust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.



What does Stoke Therapeutics do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.



What does Stoke Therapeutics's logo look like?

Stoke Therapeutics, Inc. logo

Complete history of Dr Kaye stock trades at Cytokinetics Inc, Sarepta Therapeutics Inc, Avidity Biosciences, eStoke Therapeutics

Data
#
Companhia
Acionista maioritário
Trans.
Transação
Ações Preço por ação Preço total Ações após Fonte
20 May 2024 Edward M. Md Kaye
Chefe Executivo
Venda 42,350 $15.43 $653,461
20 May 2024
27,000
15 Mar 2024 Edward M. Md Kaye
Chefe Executivo
Exercício de opção 35,500 $6.39 $226,845
15 Mar 2024
80,500
27 Mar 2023 Edward M. Md Kaye
Chefe Executivo
Exercício de opção 20,000 $0.60 $12,000
27 Mar 2023
45,000
25 May 2022 Edward M. Md Kaye
Chefe Executivo
Exercício de opção 15,000 $0.60 $9,000
25 May 2022
25,000
30 Dec 2020 Edward M. Md Kaye
Chefe Executivo
Exercício de opção 10,000 $0.60 $6,000
30 Dec 2020
10,000
17 Dec 2020 Edward M. Md Kaye
Chefe Executivo
Venda 25,000 $60.00 $1,500,000
17 Dec 2020
0
27 Nov 2020 Edward M. Md Kaye
Chefe Executivo
Venda 12,152 $50.00 $607,600
27 Nov 2020
25,000
25 Nov 2020 Edward M. Md Kaye
Chefe Executivo
Venda 12,848 $50.00 $642,400
25 Nov 2020
37,152
16 Dec 2019 Edward M. Md Kaye
Chefe Executivo
Exercício de opção 50,000 $0.60 $30,000
16 Dec 2019
50,000
5 Aug 2022 Edward M. Md Kaye
Diretor
Exercício de opção 11,428 $8.75 $99,995
5 Aug 2022
24,004
23 Dec 2021 Edward M. Md Kaye
Diretor
Exercício de opção 15,000 $7.61 $114,150
23 Dec 2021
21,765
5 Oct 2020 Edward M. Md Kaye
Diretor
Exercício de opção 20,000 $7.61 $152,200
5 Oct 2020
20,000
20 Jul 2017 Edward M. Md Kaye
SVP e Chief Medical Officer
Venda 10,000 $41.00 $410,000
20 Jul 2017
52,471
9 Nov 2016 Edward M. Md Kaye
SVP e Chief Medical Officer
Exercício de opção 3,000 $8.28 $24,840
9 Nov 2016
75,635
22 Sep 2016 Edward M. Md Kaye
SVP e Chief Medical Officer
Exercício de opção 40,179 $8.28 $332,682
22 Sep 2016
117,162
19 Sep 2016 Edward M. Md Kaye
SVP e Chief Medical Officer
Exercício de opção 24,352 $6.94 $169,003
19 Sep 2016
87,388
14 Sep 2016 Edward M. Md Kaye
SVP e Chief Medical Officer
Venda 24,557 $30.00 $736,710
14 Sep 2016
76,983
14 Sep 2016 Edward M. Md Kaye
SVP e Chief Medical Officer
Venda 24,557 $30.00 $736,710
14 Sep 2016
76,983
27 Feb 2015 Edward M. Md Kaye
SVP e Chief Medical Officer
Comprar 800 $11.82 $9,456
27 Feb 2015
1,311


Stoke Therapeutics executives and stock owners

Stoke Therapeutics executives and other stock owners filed with the SEC include: